Literature DB >> 14620497

A framework for monitoring the malaria eradication programme in Korea.

Moo-Sik Lee1, Kun-Sei Lee, Byung-Kuk Yang, Dae-Seong Kim, Beom-Man Ha, Kidong Park, Eun-Young Kim, Yong-Ik Kim.   

Abstract

The World Health Organisation established the Roll Back Malaria (RBM) strategy to reduce the global burden of malaria in 1998. A set of RBM indicators will not be suitable to the Republic of Korea due to the differences of the epidemiological and socio-cultural situation. Therefore, we have developed a framework and indicators for monitoring the outcomes and impact of the national malaria eradication programme that are appropriate for the situation in Korea. We reviewed the existing data in the national malaria eradication programme. We adopted general principles in developing a monitoring framework and indicators for monitoring RBM. Monitoring areas were recombined components and content that included the project plan, training health personnel, health education and public information, supply for manpower, equipment and materials, disease control, information system, supervision, community participation, intersectoral collaboration within practical guidelines for the national malaria eradication programme along with malaria control and RBM strategy of WHO. Twenty one monitoring areas were selected that identified critical areas for the national malaria eradication programme. Fifteen indicators of ten categories are proposed for use by the national malaria eradication programme in Korea.

Entities:  

Mesh:

Year:  2003        PMID: 14620497     DOI: 10.1177/101053950301500108

Source DB:  PubMed          Journal:  Asia Pac J Public Health        ISSN: 1010-5395            Impact factor:   1.399


  1 in total

1.  Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea.

Authors:  Eun-Taek Han; Duk-Hyoung Lee; Ki-Dong Park; Won-Seok Seok; Young-Soo Kim; Takafumi Tsuboi; Eun-Hee Shin; Jong-Yil Chai
Journal:  Korean J Parasitol       Date:  2006-12       Impact factor: 1.341

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.